.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The Serum Midkine HCC biomarker is transforming the management of liver malignancies, particularly in cases where traditional markers fall short. While alpha-fetoprotein (AFP) remains the standard, it often lacks the sensitivity required for early detection or monitoring AFP-negative patients. Recent clinical studies demonstrate that Midkine offers a more reliable alternative for assessing disease progression and treatment response. Consequently, this biomarker effectively differentiates between benign liver diseases and malignant hepatocellular carcinoma (HCC).
Research indicates that Midkine levels correlate strongly with critical clinicopathological features, including tumor size and Barcelona Clinic Liver Cancer (BCLC) stages. Therefore, higher serum concentrations often signal advanced clinical stages and poor prognosis. Furthermore, clinicians find this marker helpful in characterizing patients who do not show elevated AFP levels. Notably, Midkine’s efficacy in evaluating treatment efficacy is comparable to advanced imaging techniques like CT and MRI. This correlation is particularly beneficial for monitoring patients undergoing non-surgical therapies.
Moreover, multivariate regression models identify Midkine as a key predictive factor for hepatocellular carcinoma. By tracking these levels, healthcare providers can better evaluate the likelihood of disease recurrence or metastasis. Additionally, Midkine levels significantly decrease following successful tumor resection, making it an excellent tool for post-operative surveillance. Therefore, integrating Midkine into routine oncology protocols could lead to more personalized and effective treatment strategies for liver cancer patients.
Midkine exhibits high sensitivity even in patients with normal AFP levels, allowing for the detection and monitoring of HCC cases that might otherwise be missed.
Serum Midkine levels tend to decrease after successful intervention and rise during disease progression, providing a biochemical indicator of treatment efficacy similar to imaging scans.
Disclaimer: This content is for informational and educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.
References
1. Luo Y et al. Serum Midkine as a Biomarker for Hepatocellular Carcinoma Treatment Response and Prognostication. J Clin Lab Anal. 2026 May 25. doi: 10.1002/jcla.70255. PMID: 42184120.
2. Lu Q, et al. Comparison of diagnostic accuracy of Midkine and AFP for detecting hepatocellular carcinoma: a systematic review and meta-analysis. Biosci Rep. 2020;40(3):BSR20192424.
3. Zheng et al. Midkine (MDK) in Hepatocellular Carcinoma: More than a Biomarker. MDPI. 2024;16(2):112.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Serum Midkine emerges as a superior biomarker for HCC, specifically in AFP-negative patients, offering high sensitivity for monitoring treatment response....
3 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
